Bevacizumab in Patients With Metatstatic Renal Cell Carcinoma or Others Advanced Solid Tumors.

Trial Profile

Bevacizumab in Patients With Metatstatic Renal Cell Carcinoma or Others Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Pazopanib (Primary)
  • Indications Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms PARASOL
  • Most Recent Events

    • 01 Jun 2014 Status changed from active, no longer recruiting to completed according to results published in the Cancer Chemotherapy and Pharmacology.
    • 24 Dec 2013 Planned End Date changed from 1 Mar 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 24 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top